Nasus Pharma Ltd. (NSRX)

Nasus Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	0.96	0.74	0.58	0.93
Research & Development	0.46	0.34	0.57	1.12
Operating Expenses	1.41	1.08	1.15	2.04
Operating Income	-1.41	-1.08	-1.15	-2.04
Interest Expense	-0.01	-0.03	-0.05	-0.02
Other Non Operating Income (Expenses)	-0.05	-0	-0.03	-0
EBT Excluding Unusual Items	-1.47	-1.11	-1.22	-2.06
Gain (Loss) on Sale of Investments	-0.39	-0.44	0.22	-0.09
Pretax Income	-1.86	-1.55	-1.01	-2.15
Earnings From Continuing Operations	-1.86	-1.55	-1.01	-2.15
Earnings From Discontinued Operations	-0.05	0.02	-0.05	0.44
Net Income	-1.91	-1.53	-1.05	-1.71
Net Income to Common	-1.91	-1.53	-1.05	-1.71
Shares Outstanding (Basic)	7	7	7	7
Shares Outstanding (Diluted)	7	7	7	7
Shares Change (YoY)	5.44%	-0.43%	2.44%	-
EPS (Basic)	-0.26	-0.22	-0.15	-0.25
EPS (Diluted)	-0.26	-0.22	-0.20	-0.25
EBIT	-1.41	-1.08	-1.15	-2.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q